Freshfields represented SERB Pharmaceuticals, a global specialty pharmaceutical company, on its agreement with SFJ Pharmaceuticals, a global drug development company, to acquire exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ. More details about bentracimab and the transaction can be found here. Freshfields served as legal counsel for SERB. The deal team was led […]
The post Freshfields Advises SERB Pharmaceuticals on its U.S. Partnership with SFJ Pharmaceuticals appeared first on Legal Desire Media and Insights.